Physician profile

Mark Alkass

Obstetrics & Gynecology · Davenport, FL

NPI 1528010535

$3,869.08

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$326.61

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Intuitive Surgical, INC. $3,017.46 2019-2022
Baxter Healthcare $662.25 2019-2024 Tisseel
Hologic Sales and Service, LLC $70.24 2022-2024 Aptima, Thinprep 2000 Processor
Osiris Therapeutics INC. $42.30 2019
Abbvie INC. $22.11 2023 Liletta
Amag Pharmaceuticals, INC. $14.61 2019
Therapeuticsmd, INC. $13.99 2019
Lupin INC. $13.30 2019
Ethicon US, LLC $12.82 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Mark Alkass

$3,869.08

in general payments reported 2019-2025

Years
2019-2024
Top company
Intuitive Surgical, INC.

https://glasscript.com/doctor/341520/mark-alkass

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.